FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14 | Pharmafile
Novartis cancer therapy MET inhibitor capmatinib granted USFDA priority review
Real-world insights into patients with advanced NSCLC and MET alterations - Lung Cancer
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer | Novartis
Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA
Has PD-1 MET Its Match in Hepatocellular Carcinoma? - Gastroenterology
Biomedicines | Free Full-Text | Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment | HTML
FDA approves Tabrecta for treatment of metastatic NSCLC
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study - The Lancet Oncology
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor - Journal of Thoracic Oncology
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Novartis' MET inhibitor Tabrecta wins permit for lung cancer in Korea < Pharma < 기사본문 - KBR
Kinase drug discovery 20 years after imatinib: progress and future directions | Nature Reviews Drug Discovery
Merck KGaA matches Novartis with FDA green light for targeted lung cancer drug Tepmetko | Fierce Pharma
Capmatinib (INC280) | Selective MET Inhibitor | MedChemExpress
Novartis promising anti-tumor combination therapy - K-Recruiting
Novartis' Powerful MET Inhibitor Tabrecta Has A Strong Therapeutic Effect On METex14 Mutant Non-small Cell Lung Cancer (NSCLC)! - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
Novartis bags FDA priority review in tight lung cancer race against Merck KGaA | Fierce Pharma
Novartis gets FDA nod for Tabrecta to treat metastatic NSCLC with METex14 - Chemdiv
Contemporary Developments in MET-Selective Kinase Inhibitors in Advanced Non–Small-Cell Lung Cancer
Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14 | Novartis
JCM | Free Full-Text | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer | HTML
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Metabolism of c-Met Kinase Inhibitors Containing Quinoline by Aldehyde Oxidase, Electron Donating, and Steric Hindrance Effect | Drug Metabolism & Disposition
Novartis Reports Results of Capmatinib in P-II GEOMETRY mono-1 Study for Non-Small Cell
